

Not an Epidemic? Controversies in Substance Abuse

Richard C. Dart, MD, PhD

Director, Rocky Mountain Poison and Drug Safety, Denver Health

Executive Director, RADARS® System

Professor, University of Colorado School of Medicine

Competing Interests


RADARS® System is the property of The Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado.

RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and nongovernment agencies for surveillance, research, and reporting services. No subscriber participated in the conception, analysis, drafting, or review of this presentation.





Real World Evidence and Triangulation






What Is The Problem?

Drug-Related Deaths Are Increasing

Drug overdose deaths in the U.S.

Annual deaths ending in June of each year below



\$1.6 TRILLION in 2020

Note: Chart shows provisional figures. • Source: Centers for Disease Control and



Problem: Demand for Drugs of Abuse

How Did We Get Here? The Federal Narrative

• 1990s

- Pharmaceutical companies and pain experts reassured the medical community that patients would not become addicted to opioid pain relievers
- Health care providers began to prescribe them at greater rates.
- Increased prescription of opioid medications led to widespread misuse of both prescription and non-prescription opioids before it came clear that these medications could indeed be highly addictive.

• 2017

 HHS declared a public health emergency and announced a five point strategy to combat the opioid crisis emphasizing Rx opioids



OxyContin Started It All?

- Dopesick
- "It aims to explore the scandal from the Sacklers down, opening with the development of the drug in the 1980s, to show how greedy bosses and avaricious sales reps were able to hijack the good intentions of doctors all over the country," Wikipedia
- What do the data say?

PAIN KILLER


of a
Prescription
Drug Disaster

Barry Meier 2003




ER Products Like OC Are Small Fraction of Rx Illicit Drug Supply

RADARS® System Drug Diversion





RADARS® System Drug Diversion





The Role of OxyContin in Opioid Crisis










What Actually Happened?

- Health care systems and regulation
 - Fifth vital sign, patient "satisfaction," etc.
- Careless doctors
 - We knew better, but convenience won us over. WILLING TEXT
 - Malicious behavior pill mills
- Opioid marketing
 - Aggressive, irresponsible
- Insufficient treatment options for Opioid Use Disorder (OUD)
- "Patient demand"



All Measures of <u>Prescription</u> Opioid Use Are Decreasing

All Prescription Opioids, Individually or Combined






HOW CAN WE HAVE DECREASING PRESCRIPTION OPIOID ABUSE, BUT INCREASING DEATHS?




Drug Overdose Deaths are Dominated by Synthetic Opioids




All Measures of Illicit Fentanyl Use Are Increasing

Non-Rx Fentanyl






The Role of "Counterfeit" Drugs Drug Diversion Program – Increase in "Oxycodone" Cases






Nonmedical Use is Increasing Slowly, but Mortality is Increasing Rapidly

Total Nonmedical Use of Psychotropics



National Survey of Drug Use and Health

Opioid-Related Mortality



NVSS, CDC



Demand and Supply

It's Not the Drug



- As a recovering substance abuser, I know that no pharmaceutical giant ever pushed a pill down my throat. I did it myself. Now I'm beginning to discover why.
 - Jeffrey Gratton, Long Island, NY Aug 19, 2001 (NYT)

Drugs are not my problem.
Reality is my problem.
Drugs are my solution.

Russell Brand

RECOVERY

FREEDOM FROM OUR ADDICTIONS

RUSSELL BRAND



Drug Exposure Nicotine - Alcohol - Cannabis - Etc.

Risk Factors


Family Dysfunction **Emotional Abuse** Isolation

Risk Factors

Physical Abuse Trauma Genetics

Move to POLYSUBSTANCE ABUSE

Polysubstance Abuse



- **Amphetamine**
- Methylphenidate
- **Designer drugs**

- **LSD**
- **Psilocybin**

- **Cathinones**
- Synth Cann'oids

OCKY MOUNTAIN **POISON & DRUG SAFETY**

Saving lives with answers.™

Supply and Demand

- Supply generally increases to meet demand
 - Why is demand for drugs so high in the United States?
 - And what will that supply look like?
- Demand Reduction
 - Buprenorphine
 - Methadone
 - Primary reduction?




What Does the Future Hold?


RADARS System, Rx Stimulant Rates, 2008 - 2020

Poison Center Program

Cases per 100,000 population





Drug Diversion Program





Stimulants - Increasing Mortality over Time






Black J, et al. Association of Medical Stimulants With Mortality in the US From 2010 to 2017 doi:10.1001/jamainternmed.2020.7850




3 Million Adults Have Used Kratom, NMURx, 2018-2019

Kratom Abuse Profile More Severe Than Prescription Opioids






Nonmedical Use of Loperamide (Immodium) in UK and US, NMURx, 2017






Increasing Diversion of Nonscheduled Psychoactive Prescription Medications





MDMA-assisted Therapy for Severe PTSD



Mitchell, J.M., Bogenschutz, M., Lilienstein, A. *et al. Nat Med* **27**, 1025–1033 (2021). https://doi.org/10.1038/s41591-021-01336-3







DRUG DEVELOPMENT SNAPSHOT

- 113 CLINICAL TRIALS FOR MDMA
- 99 CLINICAL TRIALS FOR PSILOCYBIN
- 29 CLINICAL TRIALS FOR LYSERGIC ACID DIETHYLAMIDE (LSD)



A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma


Latest Issues

SCIENTIFIC

AMERICAN.

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

y Yasemin Saplakoglu published November 25, 2019



Source: Clinicaltrials.gov, Accessed 2/16/22; 5/16/22

1.. Carhart- Harris, et al (2021). Trial of psilocybin versus escitalopram


Trial of psilocybin versus escitalopram for depression. New England Journal of Med.; 384: 1402-1411


2. Mitchell JM, et. al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. In Nature Med.; 27: 1025-1033

 $\bullet lmages: \underline{https://fortune.com/2022/01/26/fda-clears-lsd-based-drug-clinical-trials/;} \underline{https://www.livescience.com/psilocybin-depression-breakthrough-therapy.html;}$

Psychedelic Module

- IN 2020, 2.6% OF PEOPLE AGED 12+ (OR 7.1M PEOPLE) USED HALLUCINOGENS IN THE PAST YEAR
- 1.4M PEOPLE INITIATED HALLUCINOGEN USE IN THE PAST YEAR, INCLUDING 251,000 ADOLESCENTS





2020 NSDUH Annual National Report | CBHSQ Data (samhsa.gov)

Note: category of hallucinogens includes LSD, PCP, peyote, mescaline, psilocybin, MDMA, ketamine, DMT and Salvia divinorum



Summary

- Opioid deaths are still rising
 - Mainly due to synthetic opioid analog
 - Counterfeit drugs rising
 - Illicit fentanyl continues to rise
- Most patients misuse more than one drug
- Most deaths involve more than one drug
- On the horizon: stimulants, OTCs, antipsychotics, psychedelics



Questions?

Richard.Dart@rmpds.org

www.RADARS.org

